Naftifine clinical trials
Also written NAFT-500.
How each study uses naftifine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 29 Feb 1988 · NAFTIN · NDA 019599 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Merz North America, Inc. (6) · Taro Pharmaceuticals USA (3) · Genzum Life Sciences (1)
Studies
Open first, then newest update. How each study uses naftifine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea PedisCompletedPhase 1Taro Pharmaceuticals USANCT02335255Written as Naftifine Hydrochloride Gel 2%
- BE Study of Naftifine HCLCompletedPhase 3Genzum Life SciencesNCT02633813Written as Naftifine hydrochloride 2%
- Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea PedisCompletedPhase 1Taro Pharmaceuticals USANCT02132260Written as Naftifine Hydrochloride Cream 2%
- Pediatric Subjects With Tinea CorporisCompletedPhase 4Merz North America, Inc.NCT02227290Written as Naftin Cream
- Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea PedisCompletedPhase 4Merz North America, Inc.NCT01712360Written as NAFT500 (pediatric)
- Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea CrurisCompletedPhase 3Merz North America, Inc.NCT01885156Written as Naftin 1% Cream
- Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea PedisCompletedPhase 1Taro Pharmaceuticals USANCT01580891Written as Naftifine HCl Cream 1%
- Efficacy and Safety of NAFT-600 in Subjects With Tinea PedisCompletedPhase 3Merz North America, Inc.NCT01289015Written as NAFT-600 ( naftin 2 % gel )
- Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea PedisCompletedPhase 3Merz North America, Inc.NCT00750139Written as NAFT-500
- Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea CrurisCompletedPhase 3Merz North America, Inc.NCT00750152Written as NAFT-500
As the comparator · 1 — what is tested is compared with naftifine
Codes
What other systems call naftifine · ClinicalTrials.gg INT002886
- MeSH (NLM) C029178naftifineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4FB1TON47ANAFTIFINEConfirmed FDA, NLM, Wikidata
- RxNorm 31476Confirmed FDA, Wikidata
- Wikidata Q413586naftifineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66217NaftifineOne source FDA
- DrugBank DB00735One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C029178 | naftifine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4FB1TON47A | NAFTIFINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 31476 | — | Confirmed FDA, Wikidata |
| Wikidata | Q413586 | naftifine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66217 | Naftifine | One source FDA |
| DrugBank | DB00735 | — | One source Wikidata |
Also registered as naftifine hydrochloride (UNII 25UR9N9041 · RxNorm 91293).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.